Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

During an outpatient rheumatology consultation, a 4242-year-old woman receives a new diagnosis of highly active, erosive rheumatoid arthritis. She has a past medical history of type 22 diabetes mellitus and mild intermittent asthma, currently managed with metformin and as-needed albuterol. Due to rapidly progressive joint destruction and elevated inflammatory markers, the physician plans to initiate aggressive combination therapy with methotrexate and infliximab. Physical examination reveals symmetric synovitis in the metacarpophalangeal and proximal interphalangeal joints bilaterally. The cardiovascular and pulmonary examinations are completely unremarkable, with no jugular venous distention, crackles, or edema. The patient has no history of international travel or known infectious exposures.

Which of the following baseline screening evaluations MUST be obtained prior to initiating this specific pharmacologic regimen? (Select the 2 correct answers.)

  1. Hepatitis B surface antigen and core antibodyCevap
  2. Interferon-gamma release assayCevap
  3. C
    Transthoracic echocardiogram
  4. D
    Thiopurine methyltransferase enzyme activity
  5. E
    Cytochrome P450 3A4 pharmacogenomic testing

Cevap

The mandatory baseline screening evaluations are Hepatitis B surface antigen and core antibody, and an Interferon-gamma release assay.
Biologic disease-modifying antirheumatic drugs (DMARDs), specifically tumor necrosis factor-alpha (TNF-alpha) inhibitors like infliximab, carry a profound risk of reactivating latent infections. Because TNF-alpha plays a vital role in macrophage activation and granuloma maintenance, its inhibition can lead to rapid dissemination of latent tuberculosis. Therefore, an interferon-gamma release assay (IGRA) or tuberculin skin test is universally required before starting therapy. If positive, prophylactic treatment for latent TB must be administered before the biologic is initiated. Additionally, severe and potentially fatal fulminant hepatic failure secondary to Hepatitis B virus (HBV) reactivation can occur with both methotrexate and TNF-alpha inhibitors. Current guidelines mandate screening all patients with Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis B surface antibody (anti-HBs) prior to initiating these therapies.

Adım Adım Çözüm

1
Identify the proposed pharmacologic regimen.
The patient is being started on a conventional synthetic DMARD (methotrexate) and a biologic DMARD (infliximab, a TNF-alpha inhibitor).
Different immunosuppressive medications have distinct toxicity profiles and specific screening requirements prior to initiation.
2
Determine the infectious risks associated with TNF-alpha inhibitors and methotrexate.
TNF-alpha is critical for granuloma formation and maintenance. Inhibition severely increases the risk of reactivating latent tuberculosis (TB). Furthermore, both medications carry a black-box warning for severe Hepatitis B virus (HBV) reactivation.
Immunosuppression can lead to catastrophic dissemination of subclinical infections if not identified and prophylactically treated.
3
Select the appropriate tests to screen for these specific infectious risks.
An Interferon-gamma release assay (IGRA) or tuberculin skin test is required for TB screening. Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (anti-HBc) are required for HBV screening.
These tests accurately identify latent infections that must be managed prior to administering the immunosuppressive therapy.

Anahtar Kavram

Baseline infectious disease screening for latent tuberculosis and hepatitis B is mandatory prior to initiating biologic DMARDs (like TNF-alpha inhibitors) and targeted conventional DMARDs to prevent life-threatening reactivation.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru